Compare Quest Diagnostics Inc (DGX) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs D Wave Quantum Inc — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while D Wave Quantum Inc trades at $14.57 (market cap $5.54B). The key difference: Quest Diagnostics Inc is far larger — about 4.6× D Wave Quantum Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and D Wave Quantum Inc for 32 Days on average.
| DGX | QBTS | |
|---|---|---|
Market Cap | $25.48B | $5.54B |
Volume | 941,866 | 16,671,452 |
Sector | Health | Technology |
52-Week High | $247.45 | $44.78 |
52-Week Low | $173.49 | $12.98 |
Typical Hold Time | 56 Days | 32 Days |
Enterprise Value | $31.23B | $5.04B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
QBTS (D-Wave Quantum Inc.) trades at $14.60, down 4.07% on the day, amid a bearish technical signal and negative earnings trends. The company reported a net loss of $355.06 million on $24.59 million revenue for 2025, with a deeply negative net income margin. Despite 100% analyst buy ratings and a consensus price target of $34.38, the stock faces headwinds from multiple fraud investigations and cash burn, with operating cash flow negative $72 million in 2025.
The outlook is highly speculative; while analyst optimism and quantum computing potential offer upside, significant financial losses, legal risks, and bearish technicals present substantial downside. Investors should weigh the high-risk, high-reward profile carefully, as the company's path to profitability remains uncertain amid competitive and funding challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
